Innovacell Inc. (TSE: 504A)
Health Care · Biotechnology · JP
¥544.00
-9.63% today · -59.7% 1Y
Innovacell Inc. (TSE: 504A) operates in the Biotechnology industry within the Health Care sector. The company is valued at $155.13M and employs 48 people.
Over the last twelve months the share price has lost 59.7%, trading between 377.00 and 1.25K.
Tweenvest scores Innovacell Inc. across four factors: quality 49/100, value 48/100. Its strongest factor is quality.
504A price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $155.13M
- Revenue (TTM)
- $98.43K
- P/E
- —
- EPS
- -87.45
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- ¥1,248.00
- 52-week low
- ¥377.00
- Avg volume (3M)
- —
- Shares outstanding
- 45.15M
- Employees
- 48
- Next earnings
- —
About Innovacell Inc.
Innovacell Inc. is a biotech company that develops, manufactures, and sells cell therapy and regenerative medicine products aimed at treating fecal and urinary incontinence. The company's pipeline includes treatments for urgent fecal incontinence, leaky fecal incontinence, and stress urinary incontinence using the patient's own cells.
- ISIN
- JP3147850006
- Founded
- 2021
- Listed since
- Feb 24, 2026
- Exchange
- The Tokyo Stock Exchange
- Currency
- JPY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Organogenesis Holdings Inc.NasdaqCM: ORGO | $158.27M | $1.23 | -4.65% |
| Jyong Biotech Ltd.NasdaqGM: MENS | $155.89M | $2.10 | 0.00% |
| BNC KOREA, Inc.KOSDAQ: A256840 | $155.68M | ₩3,060.00 | -3.01% |
| Helixmith Co., LtdKOSDAQ: A084990 | $155.16M | ₩4,530.00 | +22.60% |
| Mycenax Biotech Inc.TPEX: 4726 | $154.11M | NT$23.80 | +2.59% |
| Tiziana Life Sciences LtdNasdaqCM: TLSA | $153.88M | $1.09 | -8.40% |
| NovaBridge BiosciencesNasdaqGM: NBP | $153.12M | $1.32 | -5.38% |
| BioInvent International AB (publ)OM: BINV | $152.68M | Skr23.10 | -0.43% |
Figures last refreshed Oct 11, 2026.